Oxford BioDynamics (LON:OBD) Stock Price Down 5.1% – Time to Sell?

Oxford BioDynamics Plc (LON:OBD)’s share price was down 5.1% during trading on Wednesday . The company traded as low as GBX 0.45 ($0.01) and last traded at GBX 0.45 ($0.01). Approximately 400,000 shares traded hands during trading, a decline of 98% from the average daily volume of 22,854,418 shares. The stock had previously closed at GBX 0.48 ($0.01).

Analyst Ratings Changes

Separately, Shore Capital reiterated a “house stock” rating on shares of Oxford BioDynamics in a research note on Thursday, March 13th.

Oxford BioDynamics Stock Performance

The stock has a market capitalization of £8.14 million, a P/E ratio of -0.08 and a beta of 0.42. The stock’s 50-day simple moving average is GBX 0.52 and its 200 day simple moving average is GBX 1.27. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80.

Oxford BioDynamics (LON:OBD) last announced its quarterly earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.